Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

CME/CE Podcast: Personalized Antidepressant Choices for Better Outcomes

33:08
 
Share
 

Manage episode 523427294 series 2878447
Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266

Summary
Emphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

  • Assess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDD
  • Implement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomes

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

  continue reading

124 episodes

Artwork
iconShare
 
Manage episode 523427294 series 2878447
Content provided by NACE. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NACE or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266

Summary
Emphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

  • Assess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDD
  • Implement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomes

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

  continue reading

124 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play